. Author manuscript; available in PMC: 2024 Jun 3.

Published in final edited form as: Value Health. 2023 Feb 18;26(8):1155–1163. doi: 10.1016/j.jval.2023.02.007

Table 1.

US EQ-5D-5L and EORTC QLU-C10D utility linear mixed model estimated coefficients for progression-based Models 1a and 1b, by IRC progression status

	EQ-5D-5L		EORTC QLU-C10D
	Model 1a^*	Model 1b^†	Model 1a^*	Model 1b^†
Intercept^‡ (SE)	0.7271 (0.0142)	0.7166 (0.0201)	0.7271 (0.0107)	0.7211 (0.0151)
Post-progression (SE)	−0.0682 (0.0112)	−0.0683 (0.0112)	−0.0441 (0.0085)	−0.0442 (0.0085)
Previously treated (SE)	–	0.0207 (0.0279)	–	0.0117 (0.0211)

Coefficients for significant covariates are shown in bold.

Includes a random intercept and fixed effect for progression status.

^†

Includes a random intercept and fixed effects for progression status and prior treatment status.

^‡

Corresponds to pre-progression utilities overall (Model 1a) or pre-progression utilities in treatment-naïve patients (Model 1b).

EORTC, European Organisation for Research and Treatment of Cancer; IRC, independent review committee; QLU-C10D, Quality of Life Utility Measure Core 10 Dimensions; SE, standard error.